Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus

Table 5 Unadjusted sensitivity analysis for factors associated with hepatic decompensation

	OR	95%CI	P value
Demographics and clinical characteristics
Age (yr)	1.03	0.92-1.16	0.67
Gender, female	2.23	0.26-19.54	0.63
Race, black	2.2	0.04-35.75	0.94
Ethnicity, Hispanic	0.39	< 0.01-2.30	0.41
Weight (lbs)	0.99	0.96-1.02	0.37
BMI (kg/m2)	0.94	0.75-1.16	0.61
Years since Transplant	0.96	0.79-1.15	0.63
Comorbidities
Hepatocellular Carcinoma	0.28	0.01-2.94	0.49
Diabetes	2.21	0.28-27.69	0.66
Hypertension	3.22	0.30-173.80	0.57
Depression	0.86	< 0.01-5.35	0.90
Liver disease severity
Cirrhosis	5.41	0.61-56.98	0.14
FIB-4	1.11	0.94-1.31	0.24
FIB-4, ≥ 3.25	2.81	0.26-151.24	0.67
Treatment naïve	4.85	0.50-58.79	0.21
Treatment Regimen
SOF/RBV	REF	REF	REF
SOF/PEG/RBV	< 0.01	< 0.01-> 99.99	0.97
Genotype
1	REF	REF	REF
2	4.67	0.32-68.03	0.26
3	2.33	0.19-28.25	0.51
4	9.33	0.46-190.63	0.15
Labs
Hemoglobin (g/dL)	0.17	0.04-0.75	0.02
(Ref: 13.9-16.3 g/dL)
Platelets (× 103/μL)	0.99	0.97-1.01	0.29
(Ref: 150-450 × 103/μL)
HCV viral load [log10 (IU/mL)]	0.79	0.29-2.18	0.65
(Ref: 15-108 IU/mL)
Serum creatinine (mg/dL)	3.12	0.99-9.77	0.05
(Ref: 0.70-1.40 mg/dL)
eGFR (mL/min per 1.73 m2)	0.92	0.86-0.99	0.02
Albumin (g/dL)	0.13	0.02-0.58	< 0.01
(Ref: 3.5-4.9 g/dL)
ALT (U/L)	0.96	0.90-0.99	0.03
(Ref: 1-53 U/L)
AST (U/L)	0.99	0.98-1.01	0.70
(Ref: 1-50 U/L)
INR	1.59	1.09-2.97	< 0.01
Total bilirubin (mg/dL)	5.65	0.99-32.34	0.05
(Ref: 0.1-1.2 mg/dL)
Alpha fetoprotein (ng/mL)	1.03	0.98-1.08	0.27
(Ref: 0.0-9.0 ng/mL)

BMI: Body mass index; SOF: Sofosbuvir; RBV: Ribavirin; PEG: Pegylated interferon; eGFR: Estimated glomerular filtration rate; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio.